Founding Director of Whitehead Institute (1982-1990)
1200 East California Boulevard
Pasadena, CA 91125
While at Whitehead Institute, David Baltimore focused on identifying the key transcription factor NF-κB , developing a transgenic mouse line that modeled fatal leukemia, determining that RAG-1 and RAG-2 rearrange immunoglobulin genes, which increases the specificity the immune system has toward an antigen, and identifying the fusion protein bcr-abl that can ultimately cause chronic myelogenous leukemia (CML) and is deactivated by the anticancer drug Imatinib (Gleevec). Baltimore is now the President Emeritus and Distinguished Professor of Biology at the California Institute of Technology.